Collectively, the detection of GCN5L1 expression may be a useful biomarker for the use of glutaminase inhibitors for therapeutics not only against HCC but also targeting other glutamine‐addicted malignancies. This evidence concerns the gene BLOC1S1 and hepatocellular carcinoma.